These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30085157)

  • 1. Composite QA for intensity-modulated radiation therapy using individual volume-based 3D gamma indices.
    Han C; Yu W; Zheng X; Zhou Y; Gong C; Xie C; Jin X
    J Radiat Res; 2018 Sep; 59(5):669-676. PubMed ID: 30085157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individual volume-based 3D gamma indices for pretreatment VMAT QA.
    Yi J; Han C; Zheng X; Zhou Y; Deng Z; Xie C; Jin X; Jin F
    J Appl Clin Med Phys; 2017 May; 18(3):28-36. PubMed ID: 28318101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on the effect of detector resolution on gamma index passing rate for VMAT and IMRT QA.
    Woon W; Ravindran PB; Ekayanake P; S V; Lim YY; Khalid J
    J Appl Clin Med Phys; 2018 Mar; 19(2):230-248. PubMed ID: 29460465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA.
    Zhen H; Nelms BE; Tome WA
    Med Phys; 2011 Oct; 38(10):5477-89. PubMed ID: 21992366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram.
    Stasi M; Bresciani S; Miranti A; Maggio A; Sapino V; Gabriele P
    Med Phys; 2012 Dec; 39(12):7626-34. PubMed ID: 23231310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive and clinical-oriented evaluation criteria based on DVH information and gamma passing rates analysis for IMRT plan 3D verification.
    Yi X; Lu WL; Dang J; Huang W; Cui HX; Wu WC; Li Y; Jiang QF
    J Appl Clin Med Phys; 2020 Aug; 21(8):47-55. PubMed ID: 32436351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between gamma index passing rate and clinical dosimetric difference for pre-treatment 2D and 3D volumetric modulated arc therapy dosimetric verification.
    Jin X; Yan H; Han C; Zhou Y; Yi J; Xie C
    Br J Radiol; 2015 Mar; 88(1047):20140577. PubMed ID: 25494412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of spatial resolution and noise on gamma analysis for IMRT QA.
    Huang JY; Pulliam KB; McKenzie EM; Followill DS; Kry SF
    J Appl Clin Med Phys; 2014 Jul; 15(4):4690. PubMed ID: 25207399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross verification of independent dose recalculation, log files based, and phantom measurement-based pretreatment quality assurance for volumetric modulated arc therapy.
    Han C; Yi J; Zhu K; Zhou Y; Ai Y; Zheng X; Xie C; Jin X
    J Appl Clin Med Phys; 2020 Nov; 21(11):98-104. PubMed ID: 33001540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics.
    Coleman L; Skourou C
    Med Phys; 2013 Nov; 40(11):111715. PubMed ID: 24320423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive comparison study of three different planar IMRT QA techniques using MapCHECK 2.
    Keeling VP; Ahmad S; Jin H
    J Appl Clin Med Phys; 2013 Nov; 14(6):4398. PubMed ID: 24257283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of patient DVH-based QA metrics for prostate VMAT: correlation between accuracy of estimated 3D patient dose and magnitude of MLC misalignment.
    Kadoya N; Saito M; Ogasawara M; Fujita Y; Ito K; Sato K; Kishi K; Dobashi S; Takeda K; Jingu K
    J Appl Clin Med Phys; 2015 May; 16(3):5251. PubMed ID: 26103486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking bad IMRT QA practice.
    Stojadinovic S; Ouyang L; Gu X; Pompoš A; Bao Q; Solberg TD
    J Appl Clin Med Phys; 2015 May; 16(3):5242. PubMed ID: 26103484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quality assurance method that utilizes 3D dosimetry and facilitates clinical interpretation.
    Oldham M; Thomas A; O'Daniel J; Juang T; Ibbott G; Adamovics J; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):540-6. PubMed ID: 22361085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinically relevant IMRT QA workflow: Design and validation.
    Stambaugh C; Ezzell G
    Med Phys; 2018 Apr; 45(4):1391-1399. PubMed ID: 29481698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorrect dosimetric leaf separation in IMRT and VMAT treatment planning: Clinical impact and correlation with pretreatment quality assurance.
    Sjölin M; Edmund JM
    Phys Med; 2016 Jul; 32(7):918-25. PubMed ID: 27394690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological consequences of MLC calibration errors in IMRT delivery and QA.
    Moiseenko V; Lapointe V; James K; Yin L; Liu M; Pawlicki T
    Med Phys; 2012 Apr; 39(4):1917-24. PubMed ID: 22482613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implementation and error sensitivity of a 3D quality assurance protocol for prostate and thoracic IMRT.
    Gueorguiev G; Cotter C; Turcotte JC; Crawford B; Sharp G; Mah'D M
    J Appl Clin Med Phys; 2015 Sep; 16(5):179–192. PubMed ID: 26699299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvements in treatment planning calculations motivated by tightening IMRT QA tolerances.
    Stambaugh C; Gagneur J; Uejo A; Clouser E; Ezzell G
    J Appl Clin Med Phys; 2019 Jan; 20(1):250-257. PubMed ID: 30599085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant quality assurance for intensity modulated radiotherapy plans: gamma maps and DVH-based evaluation.
    Caivano R; Califano G; Fiorentino A; Cozzolino M; Oliviero C; Pedicini P; Clemente S; Chiumento C; Fusco V
    Cancer Invest; 2014 Mar; 32(3):85-91. PubMed ID: 24499109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.